Events that Inspired Clay Siegall to Drive Seattle Genetics to its Current Success

When Dr. Clay Siegall was 19 years old, his father was diagnosed with cancer. He struggled with the illness for five years, before succumbing to it five years later. By this time, Clay Siegall was 24, but he had already been made aware of the gap which existed in the availability of therapies which would be kind to the body of the patient. The idea of creating ADC, Antibody-based Drug Conjugates. The first of the ADCs which are being set up by Seattle Genetics, ADCETRIS, was approved for public use by the FDA in 2011. Since then, the company has been listed on NASDAQ and expanded their market.

Clay states that the philosophy he had in mind when he was starting the company was scientific innovation, intensive research, and passion for assisting patients. The first of the products, ADCETRIS has been marketed globally by Takeda Pharmaceuticals and is the most trusted ADC therapy in the treatment of multiple lymphomas.

To expand the company, Clay and his partner decided to form strategic partnerships with other Pharmaceuticals. They have been in multiple strategic ADC licenses with companies such as Genentech, GlaxoSmithKline, AbbVie, and Pfizer. These are the partnerships which have helped the company achieve their current level of success. The partnership has generated more than $350 million for Seattle Genetics. Siegall has also led the company in some private and public funding drives for the company, through which he has managed to raise more than $1.2 billion to support various functions of the business.

Before he started Seattle Genetics, Clay worked with The National Cancer Institute, and Bristol-Myers Squibb. He states that his main aim is to ensure that today’s cancer’s patients do better than they did in the past, and the creation of ADCs is the best way to make it happen. The next step for Seattle Genetics is to push the 11 other ADCs they have been working on to get approved. To make this happen, they have expanded their facilities. Clay says that contrary to what most companies do after making it huge, Seattle Genetics will not be selling out to any other Big Pharmaceutical.

Categories: Biotechnology